High Prevalence of Obesity and Related Complications with Limited Utilization of Obesity Medication in Patients with Psoriasis or Psoriatic Arthritis: Real-World Clinical Insights from the US

Main Article Content

Mark Lebwohl
Icahn School of Medicine at Mt. Sinai, New York, USA

Orrin Troum
Keck School of Medicine, University of Southern California, Los Angeles, California, USA

Jeffrey R. Curtis
University of Alabama at Birmingham, Alabama, USA

Andrew Blauvelt
Blauvelt Consulting, Annapolis, Maryland, USA

Ronald Prussick
The Department of Dermatology, The George Washington School of Medicine & Health Sciences, Washington DC, USA

Sakil Syeed
Eli Lilly and Company, Indianapolis, Indiana, USA

Beth Mitchell
Eli Lilly and Company, Indianapolis, Indiana, USA

Najwa Somani
Eli Lilly and Company, Indianapolis, Indiana, USA

Natalia Bello
Eli Lilly and Company, Indianapolis, Indiana, USA

Marie Louise Edwards
Analysis Group Inc., Boston, Massachusetts, USA

Joseph F. Merola
Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center, Dallas, Texas, USA

Keywords

Obesity, Psoriasis, psoriatic arthritis, Real World Evidence, Obesity medication

References

1. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. (2019)

2. ACR/NPF Joint Guideline for the Treatment of Psoriatic Arthritis. (2018)

3. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. (2022)

4. ZEPBOUND® PI, FDA, 2024.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/2eee8k43

Article Details

How to Cite
1.
High Prevalence of Obesity and Related Complications with Limited Utilization of Obesity Medication in Patients with Psoriasis or Psoriatic Arthritis: Real-World Clinical Insights from the US. J of Skin. 2025;9(6):s639. doi:10.25251/2eee8k43
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>